| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Fernanda Bruschi Priviero | Q53325359 |
| P2093 | author name string | R Clinton Webb | |
| P2860 | cites work | NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272 | Q24798007 |
| Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system | Q28201940 | ||
| NO-independent regulatory site on soluble guanylate cyclase | Q32165040 | ||
| Guanylyl cyclases and signaling by cyclic GMP. | Q33917038 | ||
| Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling | Q46877903 | ||
| Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms | Q46877927 | ||
| Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide | Q47910766 | ||
| Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure | Q48260348 | ||
| Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs. | Q48632087 | ||
| Soluble guanylyl cyclase activation promotes angiogenesis | Q64377535 | ||
| Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man | Q69375610 | ||
| Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase | Q69908375 | ||
| Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats | Q80284464 | ||
| Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, ne | Q80538292 | ||
| Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats | Q83190387 | ||
| YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components | Q33948966 | ||
| Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor | Q34122462 | ||
| Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats | Q34469717 | ||
| Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. | Q34623491 | ||
| Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. | Q34786286 | ||
| Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers | Q34823612 | ||
| Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension | Q34957241 | ||
| Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome | Q35009508 | ||
| Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea | Q35028147 | ||
| Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies | Q35044042 | ||
| NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle | Q35044464 | ||
| Cyclic GMP phosphodiesterases and regulation of smooth muscle function | Q35204728 | ||
| YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase | Q35872795 | ||
| Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. | Q36018283 | ||
| Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species | Q36052610 | ||
| Activation of purified soluble guanylate cyclase by protoporphyrin IX. | Q36293899 | ||
| Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? | Q36927106 | ||
| Cyclic GMP synthesis and function | Q39167928 | ||
| Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation | Q39847509 | ||
| Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. | Q40569818 | ||
| Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats | Q41903134 | ||
| YC-1, a novel activator of platelet guanylate cyclase | Q42275468 | ||
| Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators | Q42435281 | ||
| Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure | Q42645453 | ||
| A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation | Q42848232 | ||
| Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle | Q43095414 | ||
| Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury | Q43295132 | ||
| NO-independent stimulators of soluble guanylate cyclase | Q43558550 | ||
| Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. | Q44587860 | ||
| Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum | Q44602629 | ||
| Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs | Q45091740 | ||
| CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule | Q45158490 | ||
| Inhibitory effects on human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase | Q45302701 | ||
| The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. | Q45925609 | ||
| Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. | Q46006828 | ||
| BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. | Q46029902 | ||
| Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress | Q46403664 | ||
| Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers | Q46562534 | ||
| Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra. | Q46688447 | ||
| Altered vascular reactivity in mice made hypertensive by nitric oxide synthase inhibition | Q46701376 | ||
| Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice | Q46702844 | ||
| Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. | Q46712818 | ||
| Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase | Q46839590 | ||
| Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] an | Q46849909 | ||
| Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: interaction with nitric oxide | Q46863185 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 229-233 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Journal of Cardiovascular Pharmacology | Q2125808 |
| P1476 | title | Heme-dependent and independent soluble guanylate cyclase activators and vasodilation | |
| P478 | volume | 56 |
| Q46556756 | Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. |
| Q42555672 | Cinnamyl alcohol attenuates vasoconstriction by activation of K⁺ channels via NO-cGMP-protein kinase G pathway and inhibition of Rho-kinase. |
| Q35204833 | Gas what: NO is not the only answer to sexual function |
| Q35770676 | How full is our antihypertensives pipeline? |
| Q64988311 | Inhibition of ferrochelatase impairs vascular eNOS/NO and sGC/cGMP signaling. |
| Q41770411 | Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat |
| Q37887771 | Nitric oxide: a guardian for vascular grafts? |
| Q38856565 | Non-nitric oxide based metallovasodilators: synthesis, reactivity and biological studies |
| Q34139743 | Novel drugs targeting hypertension revisited |
| Q41980644 | Riociguat: PATENT-1 Study |
| Q38546917 | Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). |
| Q41869044 | Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation |
| Q38000562 | Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. |
| Q37897234 | Systems biology of HBOC-induced vasoconstriction |
| Q34179857 | Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. |
| Q57167791 | The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension |
| Q38130465 | The chemistry and biology of soluble guanylate cyclase stimulators and activators |
| Q50248443 | Vasodilatory effects of cinnamic acid via the nitric oxide-cGMP-PKG pathway in rat thoracic aorta. |
Search more.